TetraLogic Announces Pricing of Initial Public Offering of Common Stock
December 12 2013 - 6:30AM
TetraLogic Pharmaceuticals Corporation (TetraLogic) today announced
pricing of its initial public offering of 7,150,000 shares of its
common stock at a public offering price of $7.00 per share, before
underwriting discount and offering costs. All of the shares of
common stock are being offered by TetraLogic. In addition,
TetraLogic has granted the underwriters a 30-day option to purchase
up to an additional 1,072,500 shares of common stock at the same
price to cover over-allotments, if any. The shares are expected to
begin trading on the NASDAQ Global Market on December 12, 2013
under the symbol "TLOG."
The offering is expected to close on December 17, 2013, subject
to customary closing conditions.
Oppenheimer & Co. Inc., Guggenheim Securities, LLC and
Needham & Company, LLC are acting as joint book-running
managers for the offering.
TetraLogic intends to use the net proceeds of its initial public
offering to advance the clinical and pre-clinical development of
birinapant, other development programs, working capital and general
corporate purposes.
TetraLogic has filed a registration statement on Form S-1 with
the U.S. Securities and Exchange Commission (SEC) relating to the
common stock being sold in the offering. The registration statement
was declared effective by the SEC on December 11, 2013. The
offering is being made only by means of a prospectus, copies of
which may be obtained from:
Oppenheimer & Co.
Inc. |
Attention: Syndicate Prospectus
Department |
85 Broad Street, 26th Floor |
New York, NY 10004 |
Phone: (212) 667-8563 |
Email: EquityProspectus@opco.com |
|
Guggenheim Securities,
LLC |
Attention: Paul Gaydos |
330 Madison Avenue, 15th Floor |
New York, NY 10017 |
Phone: (212) 739-0700 |
Email:
paul.gaydos@guggenheimpartners.com |
|
Needham & Company,
LLC |
Attention: Prospectus Department |
445 Park Avenue, 3rd Floor |
New York, NY 10022 |
Phone: (800) 903-3268 |
Email: prospectus@needhamco.com |
A copy of the prospectus relating to the offering may also be
obtained by accessing the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused
on discovering and developing novel small molecule therapeutics
that mimic Second Mitochondrial Activator of Caspases, or
SMAC-mimetics, and are designed to cause or enable abnormal cells
that are resistant to the body's immune system to
self-destruct. Birinapant, our clinical-stage product
candidate, is currently being tested in Phase 1 and Phase 2
oncology clinical trials for hematological malignancies and
multiple solid tumors.
Forward Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements relate to future
events or TetraLogic's pre-clinical and clinical development of
birinapant and other clinical programs, future expectations, plans
and prospects. Although TetraLogic believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. TetraLogic has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under the heading "Risk
Factors" in our Registration Statement on Form S-1 originally filed
with the Securities and Exchange Commission on October 18, 2013, as
amended (Registration No. 333-191811).
Any forward-looking statements contained in this release speak
only as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT: Company Contact:
Pete A. Meyers
TetraLogic Pharmaceuticals Corporation
(610) 889-9900
pete.meyers@tetralogicpharma.com
Investor Relations Contact:
Lisa Burns
Burns McClellan, Inc.
(212) 213-0006
lburns@burnsmc.com
Ami Bavishi
Burns McClellan, Inc.
(212) 213-0006
abavishi@burnsmc.com
Media and Public Relations Contact:
Bill Berry
Berry & Company
212-253-8881
bberry@berrypr.com
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024